Ergothioneine, an adaptive antioxidant for the protection of injured tissues? A hypothesis.
Barry Halliwell, Irwin K Cheah, Chester L Drum
https://pubmed.ncbi.nlm.nih.gov/26772879/Actively Recruiting
Led by EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION · Updated on 2026-08-06
50
Participants Needed
1
Research Sites
24 weeks
Total Duration
Researchers are evaluating the effects of NVTIA4 Ergothioneine, a branded dietary supplement ingredient, on healthy aging biomarkers and skin health in adults aged 35 to 55 years. This randomized, double-blind, placebo-controlled clinical trial aims to provide high-quality evidence about the antioxidant and anti-inflammatory potential of this ingredient in promoting healthy aging and maintaining skin condition. Participants will be randomly assigned to receive either capsules containing 30 mg of NVTIA4 Ergothioneine or matching placebo capsules once daily for 12 weeks. The study includes two parallel groups and compares the effects of the ergothioneine supplement to placebo over the treatment period. During the study, participants will undergo assessments including blood tests to measure oxidative stress markers like plasma 8-Hydroxy-2-deoxyguanosine, inflammatory biomarkers, and skin evaluations for elasticity and hydration at baseline and after 12 weeks. Safety will be monitored throughout the study by tracking adverse events. Participants are expected to maintain their usual diet and lifestyle and attend scheduled visits for evaluation during the 12-week treatment period.
CONDITIONS
NVTIA® Ergothioneine for Healthy Aging and Skin Health
D
Daniel Harris
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants take either NVTIA4 Ergothioneine capsules or matching placebo capsules once daily.
Visits at the start and end of the treatment period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Barry Halliwell, Irwin K Cheah, Chester L Drum
https://pubmed.ncbi.nlm.nih.gov/26772879/Irwin K Cheah, Barry Halliwell
https://pubmed.ncbi.nlm.nih.gov/22001064/Xiaoying Tian, James L Thorne, J Bernadette Moore
https://pubmed.ncbi.nlm.nih.gov/38018890/B D Paul, S H Snyder
https://pubmed.ncbi.nlm.nih.gov/19911007/Irina Borodina, Louise C Kenny, Cathal M McCarthy...
https://pubmed.ncbi.nlm.nih.gov/32051057/EUROPEAN LIFE SCIENCE RESEARCH ASSOCIATION
Lead Sponsor